Novan has been granted a patent for a topical pharmaceutical composition containing a nitric oxide-releasing compound with a diazeniumdiolate functional group. The composition includes hydrophilic and hydrophobic components in specific ratios for effective delivery. GlobalData’s report on Novan gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Novan, Nanoparticle drug conjugates was a key innovation area identified from patents. Novan's grant share as of January 2024 was 62%. Grant share is based on the ratio of number of grants to total number of patents.
Topical pharmaceutical composition with nitric oxide-releasing co-condensed silica particles
See Also:
A recently granted patent (Publication Number: US11813284B2) discloses a novel topical pharmaceutical composition that includes a hydrophobic composition combined with a hydrophilic composition. The hydrophobic composition consists of nitric oxide-releasing co-condensed silica particles with a diazeniumdiolate functional group, a hydrophobic base, and an amphiphilic compound. The hydrophilic composition, on the other hand, is an aqueous hydrogel with a pH range of about 4 to 5, containing a buffer. The ratio of the hydrophilic composition to the hydrophobic composition in the topical pharmaceutical composition is limited to 4:1 or less, ensuring an optimal balance between the two components.
Moreover, the patent claims cover various aspects of the composition, including the presence of a phosphate buffer in the hydrophilic composition, additional components like cellulose, chitosan, or polyhydric alcohol, and the self-emulsifying nature of the topical pharmaceutical composition. The viscosity of the hydrophilic composition, the concentration of key components in the hydrophobic composition, and the pH range of the final product are also specified. Additionally, the patent extends to a kit comprising separate hydrophilic and hydrophobic compositions, each with specific ingredients and ratios, providing a comprehensive solution for stable storage and controlled release of nitric oxide from the diazeniumdiolate modified macromolecule. The method outlined in the patent involves mixing the hydrophobic and hydrophilic compositions to form an admixture, ensuring a balanced and effective delivery system for the active pharmaceutical ingredient.
To know more about GlobalData’s detailed insights on Novan, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
